A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03

Summary

A 46-week study to compare the efficacy of relamorelin with that of placebo in participants with diabetic gastroparesis (DG). At the end of the 40-week Treatment Period, participants will either continue on relamorelin or placebo for 6 additional weeks.

Timeline

Start

2018-01-24

Primary completion

2020-10-30

Completion

2020-10-30

Outcome

Outcome not reported

Stopped (Business): “The Relamorelin program is being terminated solely based on a business decision.”

Drugs

Indications